Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 7/20 | 0.61 |
| ▸ | CA1 | P00915 | 6/20 | 0.61 |
| ▸ | NAMPT | P43490 | 5/20 | 0.60 |
| ▸ | F7 | P08709 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | CA9 | Q16790 | 4/20 | 0.53 |
| ▸ | CA12 | O43570 | 3/20 | 0.53 |
| ▸ | CSF1R | P07333 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | LSS | P48449 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14726348 | 0.84 | CA2 (0.72) | CA2CA1NAMPTNPC1CA9 | |
| SCHEMBL14726356 | 0.83 | ALDH1A1 (0.67) | CA2CA1NAMPTNPC1CA9 | |
| SCHEMBL14726352 | 0.83 | RAB9A (0.66) | CA2CA1NAMPTNPC1CA9 | |
| SCHEMBL14726350 | 0.82 | CA2 (0.74) | CA2CA1NAMPTNPC1CA9 | |
| SCHEMBL1646021 | 0.78 | CA1 (1.00) | CA2CA1CA9CA12 | |
| SCHEMBL14322825 | 0.78 | NAMPT (0.56) | NAMPT | |
| SCHEMBL14726349 | 0.76 | CA2 (0.62) | CA2CA1NAMPTCA9CA12 | |
| SCHEMBL14726353 | 0.76 | CA1 (0.58) | CA2CA1NAMPTNPC1CA9 | |
| SCHEMBL20388957 | 0.76 | NAMPT (1.00) | NAMPT | |
| SCHEMBL15956967 | 0.74 | CA1 (0.53) | CA2CA1CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | UNIVERSITETET I OSLO (NO) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053392-A1 | CARBONIC ANHYDRASE INHIBITORS | CA9, CA2, CA4 | CA2 2/4885CA1 5/4885NAMPT 729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.